

*Raphaël graduated from the French business school HEC in 1993 and received a Master's in Applied Economics from Institut d'Etudes Politiques in 1994.*

*Raphaël began his career in London, where he spent seven years in the healthcare (largest private hospital group Générale de Santé International) and investment banking industries (Salomon Brothers and Goldman Sachs).*

*Raphaël joined Andera Partners in 2001 and has since contributed to the growth of the BioDiscovery funds and worked on numerous biotech and medtech investments leading to M&A to the industry and IPOs. He sits on the boards of Grey Wolf Therapeutics, AM Pharma, Exciva, Spiro and EG 427. He was also a board member of Chase Pharmaceuticals, Vessix Vascular, Axonics, Reviral, Amolyt Pharma and SoniVie, for most of them until their public listings and/or acquisitions by large pharmaceutical or medical device companies.*